Table 3.
Selected Biomarker Values for 11,369 DD2 Cohort Participants at Enrollment, Assessed from Tests Performed as Part of Routine Clinical Care or from Dedicated Analyses of Biobank Samples
| Biomarkers Measured in Routine Clinical Care | Biomarker Level | Number with Non-Missing Data |
|---|---|---|
| HbA1c, mmol/mol | 48.0 (43.0–54.0) | 10,444 (91.9%) |
| HbA1c before GLD treatment, mmol/mol | 54.0 (49.0–72.0) | 7184 (63.2%) |
| LDL cholesterol, mmol/L | 2.2 (1.7–2.9) | 9672 (85.1%) |
| Total cholesterol, mmol/L | 4.3 (3.6–5.0) | 9362 (82.3%) |
| Triglycerides, mmol/L | 1.7 (1.2–2.4) | 9839 (86.5%) |
| HDL cholesterol, mmol/L | 1.2 (1.0–1.4) | 9372 (82.4%) |
| eGFR, mL/min/1.73 m2 | 90.4 (76.9–100.2) | 9808 (86.3%) |
| Albumin-creatinine ratio, mg/g | 9.1 (5.0–23.0) | 8786 (77.3%) |
| Examples of biomarkers analyzed in DD2 biobank samples | ||
| Blood test available in biobank | - | 10,796 (95.0%) |
| Fasting blood test available in biobank | - | 8778 (77.9%) |
| Fasting serum C-peptide, pmol/L | 1140.0 (855.2–1521.0) | 7776 (68.4%) |
| Fasting plasma glucose, mmol/L | 7.2 (6.4–8.3) | 7767 (68.3%) |
| Glutamic acid decarboxylase antibodies ≥20 IU/mL | 165 (2.9%) | 5756 (50.6%) |
| MBL, µg/L | 734.7 (225.0–1634.1) | 7287 (64.1%) |
| hsCRP, mg/L | 2.0 (0.9–4.5) | 9663 (85.0%) |
Notes: Continuous data are presented as medians and quartiles. Count data are presented as n and proportions (%). All covariate definitions are presented in Supplementary Tables 1–6.
Abbreviations: eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; LDL, low density lipoprotein; HDL, high density lipoprotein; hsCRP, high sensitivity C-reactive protein; MBL, mannose-binding lectin.